tions of peripheral resistance (PR) defined blood pressure, mm Hg as PR = blood flow, ml/min are expressed as per cent of control values. Drugs were given intravenously (femoral vein) or intraarterially. When the arterial route was used, the drugs were dissolved to 0.5 ml with saline and injected in approximately 10 seconds; control injections of an equal volume of saline resulted in no significant alteration in blood flow. Change of flow was not considered significant unless it was greater than 5%.
BLOOD FLOW IN THE LIMB Total Femoral Blood Flow
Thirty dogs weighing 10 to 30 kg were used. After the right and left femoral arteries were exposed in the femoral triangle, a short polyethylene tube was inserted into the proximal stump of the right femoral artery. The blood was then passed through the rotameter and led to the distal stump of the left femoral artery. Intra-arterial injections were made into an air bubble trap peripheral to the rotameter. The effect of ischemia was determined by interrupting blood flow for a period of 30 seconds. When the thermostromuhr was used, calibrated units were applied to the left femoral artery and/or to the vein in the femoral triangle. In these experiments intra-arterial injections of drugs were made through a polyethylene tube in the contralateral iliaca externa after tying the caudal artery. Pulse wave recordings were obtained by placing a sphygmograph transducer 8 on the intact skin of the femoral triangle over the femoral artery. Pulse and pressure waves, ECG, and phonocardiograms were recorded simultaneously on a Hellige multiscriptor apparatus. ers 9 were used to measure skin blood flow (second method) and muscle blood flow in 12 dogs weighing 8 to 15 kg. The rates of blood flow in the femoral and saphenous arteries were measured with a Shipley-Wilson rotameter. 7
SPLANCHNIC BLOOD FLOW
Renal and mesenteric blood flows were recorded in 10 dogs weighing 10 to 15 kg. The left kidney was exposed through a lumbar incision and the renal artery or vein was isolated. Initially the thermostromuhr was used; in subsequent experiments blood flow was directed, through a rotameter, from one femoral artery to the left renal artery. Mesenteric blood flow in the normally innervated mesenteric vascular bed was recorded with the thermostromuhr. The superior mesenteric artery was freed near its origin from the abdominal aorta and a calibrated flow unit was applied, taking care to leave the mesenteric plexus intact.
CEPHALIC BLOOD FLOW
Experiments were performed on 20 dogs weighing 18 to 21 kg. The techniques for measuring flow were similar to those used with femoral and renal blood flows. Both the right common and external carotid arteries, the occipital artery, and the right vertebral artery were exposed in the neck. Intra-arterial injections were made through the ipsilateral superior thyroid artery. Internal carotid artery blood flow meas-urements were made after ligation of the external carotid artery and all vessels near the bifurcation. Cerebral venous pressure was measured from a catheter in the external jugular vein; the significance of jugular pressure for the interpretation of cerebral vascular reactions has been discussed by Carpi and Virno 10 and by Bovet et al. 11
DRUGS
The following preparations were used: l-epinephrine (R.P.); nitroglycerin, 5% solution in ethanol (C. Erba); eledoisin as a highly purified extract 1 or as a synthetic product (Sandoz and Farmitalia); synthetic bradykinin,* carbaminoylcholine (Farmitalia); papaverine chloride (C. Erba); heparin (Roche); thiopentone sodium (Farmitalia); and chloralose (Merck).
Results

BLOOD FLOW IN THE LIMB
Total Femoral Blood Flow
Control. Blood flow through the femoral artery varied from an average minimum of 55 ml/min in dogs weighing 10 kg, to an average maximum of 150 ml/min in dogs weighing 20 to 30 kg. The mean systemic pressure ranged from 110 to 150 mm Hg, with an average of 130 mm Hg. No significant variations in control values of each animal occurred during the experimental period.
Ischemia. Vascular reactivity, as indicated by reactive hyperemia, was always present. The peak femoral blood flow after 30 seconds of ischemia averaged about three times the control flow, while the peripheral resistance decreased to one-third of control. Reactive hyperemia lasted 20 to 30 seconds.
Intra-arterial Injections. Blood flow responses to intra-arterial injections of eledoisin, bradykinin, nitroglycerin, and papaverine, metered by a rotameter, are summarized in table 1. The minimal active dose of eledoisin is about 0.001 nanogram/kg (ng/kg)-Typical responses to eledoisin in comparison to those of nitroglyeerin are shown in figure 1. Bradykinin is 5 to 10 times less active than eledoisin when small doses are compared in terms of femoral arterial flow. Bradykinin becomes nearly as active as eledoisin at doses higher than 0.1 ng/kg IA; nitroglycerin is 1000 times less active than eledoisin per unit weight, and papaverine is still less active. Doses of eledoisin from 0.01 to 10 ng/kg markedly decrease peripheral resistances without significantly modifying the systemic arterial pressure; e.g., 10 ng/kg IA caused a 15% decrease in peripheral resistance with a concomitant 17% decrease in systemic pressure. Higher doses markedly decreased systemic blood pressure,
FIGURE 2
Effect of increasing intra-arterial dose of eledoisin on femoral blood flow recorded by thermostromuhr. Effect of eledoisin (mol wt 1188), bradykinin (mol wt 1063), nitroglycerin (mol wt 227), carbaminoylcholine (i wt 147), papaverine (mol wt 375), and Z-epinephrine (mol wt 183) on blood flow in different beds recorded by re meter.
• c •
* ml/min = blood flow per minute; % var. = per cent variation from control blood flow; BP = mean blood pressi mm Hg; PR = per cent of control resistance to flow. thus tending to reduce flow. Femoral blood flow changes provoked by eledoisin, bradykinin, nitroglycerin, and papaverine started 6 to 10 seconds after the injections. After a rapid increase, blood flow returned to the control values in a few minutes, the effect being longer lasting following higher doses. The increased flow was sometimes followed by a slight decrease to below the control values lasting one to three minutes. Eledoisin and nitroglycerin increased femoral blood flow even when flow was recorded through the unopened blood vessel. The injection of progressively larger doses of the drugs caused corresponding increments of .flow, .as expected for a normal dose-response relation-ship ( fig. 2 ). Pulse pressures following intraarterial eledoisin are shown in figure 3; at the dose used (0.5 ng/kg) the amplitude of the pulse is increased from 6 to 17 mm and the contour is markedly modified. The usual time-relation between ECG, phonocardiogram, pressure, and pulse waves did not vary during the action of eledoisin. Pulse pressure changes started a few seconds after the injection of eledoisin and reached their maximum within 30 to 60 seconds. The effects did not last more than 5 minutes. ly the amount sufficient to increase blood flow, also caused a decrease in systemic blood pressure. However, in experiments using 0.1 ngAg eledoisin it was possible to provoke an increase in blood flow without any concomitant variation in blood pressure. Higher doses, 1, 10, and 100 ngAg, increased femoral blood flow even when blood pressure decreased markedly. Simultaneous recordings of arterial and venous blood flows have shown clearly that there is little difference between arterial and venous flows, the increase of venous blood flow beginning two to three seconds after the increase in arterial flow.
Skin and Muscle Flow
Control. Blood flow through the skin ranged between 7 and 25 ml/min with an average of 17 ml/min; flow through the muscle ranged between. 12 and .45 ml/min with an average of 30 ml/min. The flow variations Circmlttton Rtntrcb, Vol. XV, Novtmbtr 1964 following ischemia were similar to those obtained by Lanier and co-workers. 9 Little or no response to ischemia was observed in the skin, whereas reactive hyperemia was always observed in muscle. The increased flow at the peak of reactive hyperemia averaged three times the control value.
Drugs. Skin and muscle blood flow responses to intra-arterial injections are summarized in table 1. Eledoisin was active on both muscle and skin flow at doses as low as 0.001 ng/kg IA; the vascular bed of the muscles being more sensitive. Bradykinin was 10 to 50 times less active than eledoisin when small doses of these drugs (0.001 to 0.1 ng/kg) were compared in muscle. At doses higher than 0.1 ngAg bradykinin was as active as eledoisin. At these doses both drugs reached the systemic circulation thus reducing arterial perfusion pressure. How-ever, eledoisin was more active than bradykinin on arterial blood pressure. On the skin blood flow bradyldnin was nearly as active as eledoisin. Nitroglycerin, papaverine, and carbaminoylcholine increased both skin and muscle flow. Epinephrine always had a vasoconstrictor effect on the blood vessels supplying muscle and skin.
RENAL AND MESENTERIC BLOOD FLOWS
Control blood flow through the renal artery ranged from 70 to 80 ml/min, while control arterial pressure was about 100 mm Hg. Epinephrine decreased blood flow in doses which were too small to affect the systemic circulation. This effect became evident particularly when epinephrine was given intraarterially. Eledoisin and nitroglycerin had no detectable effect on the blood vessels (table  1) . Eledoisin, given intravenously, may even decrease the blood flow when doses that decrease blood pressure are used. However, it is interesting to note that eledoisin (0.005 /agAg rv), when injected simultaneously with epinephrine (1 yxg/kg rv), is able to reduce by 505? the constrictor effect of epinephrine on the renal vessels. Reactions of the mesenteric vascular bed were similar to those observed in the kidney. Intravenous injections of hypotensive doses of eledoisin reduced the blood flow through the mesenteric vascular bed supplied by the superior mesen-teric artery, while the femoral blood flow, recorded simultaneously, always increased.
CEPHALIC BLOOD FLOW
Intravenous Injection
Eledoisin increased blood flow through the right common and external carotid arteries, the occipital artery, and the vertebral artery at dosages active on femoral blood flow (0.5 to 50 ng/kg). As in previous experiments, it was not possible to dissociate the effect of eledoisin on blood flow from that on blood pressure. The average duration of the effect was similar to that observed for femoral blood flow.
Intro-arterial Injection
Blood flow through the right common carotid artery during the control period varied from 55 to 63 ml/min with an average arterial pressure of 125 mm Hg. The occlusion of all the vessels arising from the bifurcation, except the internal carotid artery, decreased blood flow to 23 ml/min ( -60%).
The effects of several doses of eledoisin, nitroglycerin, and papaverine in this preparation are summarized in table 1. Eledoisin increased blood flow in both the common ( fig.  4 ) and internal carotid arteries ( fig. 5 ). Nitroglycerin ( fig. 4 ) and papaverine were markedly less active than eledoisin in producing vasodilatation. Nitroglycerin was 1/1000 to 1/10000 as active as eledoisin on Comparison of eledoisin (left) and nitroglycerin (right) on common carotid blood flow as recorded by rotameter.
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common carotid artery blood flow. This difference in activity became more evident when the effects of these drugs on blood flow through the internal carotid artery were compared: nitroglycerin was 10,000 to 100,000 times less active. No significant differences in results were obtained when blood flow through each region of the cephalic vascular bed was recorded by the therrnostromuhr.
In some experiments internal carotid blood flow and peripheral jugular pressure were recorded simultaneously; intravenous injection of eledoisin was followed by a concomitant increase in blood flow and in cerebral venous pressure ( fig. 6 ). However, the relationship between the doses of eledoisin used and the effect on the cerebral venous pressure was not clear.
Discussion
Our results show that eledoisin has a strong vasodilator action on vessels supplying both muscle and skin of the dog. These findings agree with those obtained by Broghammer, 12 who showed that, in man, muscle blood flow may be increased more than tenfold by eledoisin.
Increased flow through the internal carotid artery suggests, but does not prove, that in-tracranial blood vessels undergo vasodilatation. Previous studies 13 ' 14 have shown many communications between the internal carotid and ipsilateral internal maxillary arteries just proximal to the alisphenoid canal. Therefore considerable interchange of flow between intra-and extracranial vascular beds may occur and eledoisin may reach extracranial structures. In contrast, eledoisin has no detectable vasodilator action on the mesenteric and renal vascular beds. Renal and mesenteric blood flows follow passively the changes in general blood pressure induced by eledoisin. The increase of pulse amplitude recorded from the femoral artery after small intra-arterial doses of eledoisin may indicate that this drug provokes a dilatation of large arteries. The peripheral vasodilator properties of eledoisin clearly explain its hypotensive effects in anesthetized 1 -*• r '-ln and unanesthetized 10 dogs. However, our results do not enable us to decide whether the dilator action of eledoisin on vascular smooth muscle is a direct or an indirect action mediated via the peripheral nervous system. Effect of 0.0005 yjg/kg, of eledoisin intravenously on blood pressure, internal carotid blood flow (recorded by thermostromuhr), and cerebral venous pressure. The increase of blood flow through the internal carotid artery and the increase of cerebral venous pressure are simultaneous and concomitant with a decrease in blood pressure. is even more remarkable when considered on a molar basis (table 2). In small doses eledoisin is often 10 to 100 times more active than bradykinin, previously considered the most active known vasodilator. At higher doses comparison between eledoisin and bradykinin is invalidated by the finding that eledoisin lowers systemic blood pressure (perfusion pressure) to a greater degree than bradykinin. These results are in accordance with those showing that bradykinin, injected intravenously, is 20 to 100 times less active than eledoisin on blood pressure 4> *• 15 ' 16 and on coronary blood flow in the dog. 4 Nitroglycerin, as in experiments on coronary blood flow, 4 was consistently less active than ele-doisin: about 5,000 times on total femoral blood flow, about 50,000 times on common carotid blood flow, and more than 50,000 times on internal carotid blood flow. A recent report 17 shows that eledoisin in human beings, acts as a potent vasodilator drug at doses which are too small to affect blood pressure.
Summary
The peripheral vasodilator action of the endecapeptide eledoisin in the anesthetized dog has been described in this paper.
Blood flow through the vascular beds supplied by the femoral artery increased following doses of eledoisin as low as 0. intravenously, and 0.001 ng/kg (8.5-10-16 moleAg) injected intra-arterially. The blood vessels of the skin were less reactive than blood vessels in muscle.
Eledoisin exerted a powerful vasodilator effect on vascular beds supplied by the common carotid, the external and internal carotid, the occipital and the vertebral arteries.
Renal and mesenteric vascular beds did not respond significantly to eledoisin.
Comparison with some other vasodilator drugs was made. Following intra-arterial doses which do not affect systemic blood pressure, eledoisin was 5 to 50 times more active than bradykinin on total femoral and muscle flows; both showed the same activity on skin flow. Nitroglycerin, carbaminoylcholine, and papaverine were even less active than bradykinin.
